Paper Details

  1. Home
  2. Paper Details

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.

Author: , AndreoneP, BallardiniG, BerardiS, BernardiM, BianchiF B, BiselliM, BolondiL, CesconM, ColecchiaA, D'ErricoA, Del GaudioM, ErcolaniG, GramenziA, GraziG L, GrigioniW, LenziM, LodatoF, LorenziniS, MazzellaG, MorelliM C, PinnaA D, PiscagliaF, RavaioliM, RodaE, SamaC, TameM R, VivarelliM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 53 patients with hepatitis C virus recurrence after liver transplantation found that pegylated-interferon alfa-2b plus ribavirin was effective in 26% of patients.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) is difficult with low response rates. AIM: To assess the safety and efficacy of pegylated-interferon (PEG-IFN) alfa-2b + ribavirin (RBV) in patients with post-LT recurrent genotype-1 HCV and to establish st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2036.2008.03761.x

データ提供：米国国立医学図書館（NLM）

A Complex Landscape: Treating Hepatitis C Recurrence After Liver Transplantation

Liver transplantation, a complex medical procedure, often involves navigating a challenging landscape. This study focuses on the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT), a formidable obstacle in the journey to recovery. The researchers conducted a clinical trial involving 53 patients with post-LT recurrent genotype-1 HCV, investigating the safety and efficacy of pegylated-interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) as a treatment option.

A Search for Solutions: Pegylated-Interferon alfa-2b and Ribavirin in Hepatitis C Recurrence

The study, a voyage through the desert of HCV recurrence, showed that while PEG-IFN alfa-2b plus RBV was effective for some patients, the overall sustained virological response (SVR) rate was modest. The researchers identified key predictors of SVR, providing valuable insights for future treatment strategies. This research, like finding a promising trail in the desert, opens up new avenues for exploring more effective treatment options.

Navigating the Desert of Hepatitis C: Understanding the Challenges

Hepatitis C recurrence after liver transplantation is a significant challenge, requiring careful management. This study highlights the need for individualized treatment plans, tailored to the specific characteristics of each patient. It emphasizes the importance of monitoring and adjusting treatment strategies based on individual responses. Just as a camel adapts to the changing desert landscape, a flexible approach to HCV treatment is crucial for achieving successful outcomes.

Dr.Camel's Conclusion

This study provides insights into the treatment of hepatitis C recurrence after liver transplantation, a challenging journey across the desert of medical complexity. The findings highlight the need for personalized treatment strategies and underscore the importance of identifying predictive factors for successful outcomes. This research, like a compass guiding a lost traveler, offers valuable information for navigating the challenges of HCV recurrence.

Date :
  1. Date Completed 2008-12-04
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18549463

DOI: Digital Object Identifier

10.1111/j.1365-2036.2008.03761.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.